

Margaritis Avgeris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3418248/publications.pdf>

Version: 2024-02-01

65
papers

2,004
citations

257101

24
h-index

264894

42
g-index

65
all docs

65
docs citations

65
times ranked

3436
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 704-713.	3.2	173
2	A new tumor suppressor role for the Notch pathway in bladder cancer. <i>Nature Medicine</i> , 2014, 20, 1199-1205.	15.2	160
3	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1923-1933.	0.6	153
4	SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. <i>Science of the Total Environment</i> , 2022, 804, 150151.	3.9	116
5	The lysine-specific methyltransferase <i>KMT2C</i> / <i>MLL3</i> regulates DNA repair components in cancer. <i>EMBO Reports</i> , 2019, 20, .	2.0	93
6	The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 2573-2581.	2.9	90
7	Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 134, 116125.	5.8	88
8	Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. <i>Biological Chemistry</i> , 2012, 393, 301-317.	1.2	79
9	Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. <i>Biological Chemistry</i> , 2010, 391, 505-511.	1.2	75
10	Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. <i>Carcinogenesis</i> , 2015, 36, 528-537.	1.3	67
11	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1291.	1.8	47
12	Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. <i>British Journal of Cancer</i> , 2018, 119, 1477-1486.	2.9	41
13	miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 963-979.	1.5	41
14	miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 453-464.	1.6	40
15	Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer. <i>Clinical Biochemistry</i> , 2008, 41, 1140-1149.	0.8	37
16	Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 801-818.	1.5	36
17	Circulating miR-146a and miR-134 in predicting drug-resistant epilepsy in patients with focal impaired awareness seizures. <i>Epilepsia</i> , 2020, 61, 959-970.	2.6	35
18	miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. <i>British Journal of Cancer</i> , 2017, 117, 801-812.	2.9	33

#	ARTICLE	IF	CITATIONS
19	tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5â€²-tRF-LysCTT Results in Disease Early Progression and Patientsâ€™ Poor Treatment Outcome. <i>Cancers</i> , 2020, 12, 3661.	1.7	31
20	Loss of miR-378 in prostate cancer, a common regulator of <i>KLK2</i> and <i>KLK4</i> , correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. <i>Biological Chemistry</i> , 2014, 395, 1095-1104.	1.2	29
21	Kallikrein-related peptidase 4 gene (<i>KLK4</i>) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. <i>Prostate</i> , 2011, 71, 1780-1789.	1.2	28
22	Circulating exosomal miRNAs: clinical significance in human cancers. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 979-995.	1.5	28
23	Expression analysis and study of <i>KLK4</i> in benign and malignant breast tumours. <i>Thrombosis and Haemostasis</i> , 2009, 101, 381-387.	1.8	26
24	miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 150-161.	1.5	26
25	Targeting kallikrein-related peptidases in prostate cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 365-383.	1.5	25
26	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. <i>Cancers</i> , 2022, 14, 24.	1.7	25
27	Seafood mislabeling in Greek market using DNA barcoding. <i>Food Control</i> , 2020, 113, 107213.	2.8	23
28	Down-regulation of kallikrein-related peptidase 5 (<i>KLK5</i>) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. <i>Clinical Proteomics</i> , 2011, 8, 5.	1.1	22
29	Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk. <i>Scientific Reports</i> , 2019, 9, 1512.	1.6	21
30	L-dopa decarboxylase (<i>DDC</i>) gene expression is related to outcome in patients with prostate cancer. <i>BJU International</i> , 2012, 110, E267-73.	1.3	20
31	Expression analysis and study of the <i>KLK15</i> mRNA splice variants in prostate cancer and benign prostatic hyperplasia. <i>Cancer Science</i> , 2010, 101, 693-699.	1.7	18
32	Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108187.	1.1	18
33	Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2018, 97, 1169-1182.	0.8	17
34	HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study. <i>PLoS ONE</i> , 2019, 14, e0215984.	1.1	17
35	Downregulated <i>KLK13</i> expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 521-532.	1.2	16
36	Combining of ETHOS Operating Ergonomic Platform, Three-dimensional Laparoscopic Camera, and Radius Surgical System Manipulators Improves Ergonomy in Urologic Laparoscopy: Comparison with Conventional Laparoscopy and da Vinci in a Pelvi Trainer. <i>European Urology Focus</i> , 2017, 3, 413-420.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. <i>Carcinogenesis</i> , 2019, 40, 965-974.	1.3	14
38	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13144.	1.8	13
39	Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study. <i>Annals of Oncology</i> , 2017, 28, 2213-2218.	0.6	12
40	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.	1.7	12
41	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8498.	1.8	11
42	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. <i>British Journal of Cancer</i> , 2022, 126, 79-90.	2.9	11
43	Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. <i>Thrombosis and Haemostasis</i> , 2011, 105, 131-137.	1.8	10
44	Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 39.e29-39.e36.	0.8	10
45	Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2023-2036.	1.2	10
46	BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 2104-2118.	1.4	10
47	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020, 41, 442-451.	1.3	10
48	Molecular Effects of Treatment of Human Colorectal Cancer Cells with Natural and Classical Chemotherapeutic Drugs: Alterations in the Expression of Apoptosis-related BCL2 Family Members, Including BCL2L12. <i>Current Pharmaceutical Biotechnology</i> , 2019, 19, 1064-1075.	0.9	10
49	Expression analysis and study of KLK4 in benign and malignant breast tumours. <i>Thrombosis and Haemostasis</i> , 2009, 101, 381-7.	1.8	10
50	Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 937.	1.8	8
51	miR-181a overexpression predicts the poor treatment response and early progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020, 147, 3560-3573.	2.3	7
52	Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in Immune Desert NSCLC. <i>Cancers</i> , 2021, 13, 1658.	1.7	5
53	Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity. <i>Cancers</i> , 2021, 13, 2446.	1.7	5
54	Overexpression of the GR Riborepressor lncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL. <i>Cancers</i> , 2021, 13, 6064.	1.7	5

#	ARTICLE	IF	CITATIONS
55	<scp>Epiâ€miRNAs</scp>: Modern mediators of methylation status in human cancers. Wiley Interdisciplinary Reviews RNA, 2023, 14, e1735.	3.2	5
56	Î”Np63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3075-3087.	1.2	4
57	Impact of three-dimensional vision in laparoscopic partial nephrectomy for renal tumors. Turkish Journal of Urology, 2021, 47, 144-150.	1.3	3
58	Jagged Ends of Cell-Free DNA: Rebranding Fragmentomics in Modern Liquid Biopsy Diagnostics. Clinical Chemistry, 2021, 67, 576-578.	1.5	3
59	Abstract 3108: PD-L1 expressing circulating tumor cells (CTCs) in patients with head and neck squamous cell carcinoma (HNSCC). , 2016, , .		3
60	Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy. Annals of Oncology, 2019, 30, v462-v463.	0.6	2
61	PDL1-expressing circulating tumor cells (CTCs) in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2015, 33, 6018-6018.	0.8	2
62	Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-Fluorouracil with or without docetaxel: retrospective analysis of EORTC24971 study.. Journal of Clinical Oncology, 2015, 33, 6061-6061.	0.8	0
63	The prognostic significance of Notch 1 intracellular domain nuclear levels in head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 6061-6061.	0.8	0
64	Biomarkers with Prognostic Potential in Prostate Cancer. Frontiers in Medicinal Chemistry, 2018, , 108-34.	0.2	0
65	The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma. Blood, 2019, 134, 5529-5529.	0.6	0